Effect of Antacid on the Pharmacokinetics of Extended-Release Formulations of Tolterodine and Oxybutynin

被引：0
|
作者：
Gayatri Sathyan
Roger R. Dmochowski
Rodney A. Appell
Cindy Guo
Suneel K. Gupta
机构：
[1] ALZA Corporation,Department of Clinical Pharmacology
[2] Vanderbilt University Medical Center,Department of Urologic Surgery
[3] Baylor College of Medicine,Scott Department of Urology
来源：
Clinical Pharmacokinetics | 2004年 / 43卷
关键词：
Drug Release; Oxybutynin; Tolterodine; Poor Metaboliser; Active Moiety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1059 / 1068
页数：9
相关论文
共 50 条
  • [31] Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder
    Bolge, Susan C.
    McDonnell, Diana D.
    Chen, Andrew
    Wan, George J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (08) : 1903 - 1912
  • [32] Extended-release formulations in epilepsy
    Verrotti, Alberto
    Salladini, Carmela
    Di Marco, Giovanna
    Pisciella, Floriana
    Chiarelli, Francesco
    JOURNAL OF CHILD NEUROLOGY, 2007, 22 (04) : 419 - 426
  • [33] Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate
    Maldonado, Rafael
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (08) : 1001 - 1014
  • [34] Pharmacokinetics and Bioequivalence Estimation of Two Formulations of Alfuzosin Extended-Release Tablets
    Al Bawab, Abdel Qader
    Alkhalidi, Bashar A.
    Albarahmieh, Esra'a
    Qassim, Sami M. A.
    Al-Saifi, Mohammad A. D.
    Al-Saifi, Bashar
    Ling, Jonathan
    Al-Qerem, Walid
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (07): : 780 - 784
  • [35] Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs
    Bach, JF
    Kukanich, B
    Papich, MG
    McKiernan, BC
    JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2004, 224 (07): : 1113 - 1119
  • [36] A Benefit-Risk Assessment of Extended-Release Oxybutynin
    Martin C. Michel
    Drug Safety, 2002, 25 : 867 - 876
  • [37] Oxybutynin Extended Release and Tolterodine Immediate ReleaseA Health Economic Comparison
    D. Getsios
    J. J. Caro
    K. J. Ishak
    W. El-Hadi
    K. Payne
    M. O’Connel
    D. Albrecht
    W. Feng
    D. Dubois
    Clinical Drug Investigation, 2004, 24 : 81 - 88
  • [38] Update on tolterodine extended-release for treatment of overactive bladder
    Omotosho, Tola
    Chen, Chi Chiung Grace
    RESEARCH AND REPORTS IN UROLOGY, 2010, 2 : 185 - 191
  • [39] Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET)
    Sussman, D
    Garely, A
    CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) : 177 - 184
  • [40] A benefit-risk assessment of extended-release oxybutynin
    Michel, MC
    DRUG SAFETY, 2002, 25 (12) : 867 - 876
12345